{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:01:47Z","timestamp":1793793707946,"version":"4.6.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["2018266781"],"award-info":[{"award-number":["2018266781"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["COCR23PRF027"],"award-info":[{"award-number":["COCR23PRF027"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31HD105398"],"award-info":[{"award-number":["F31HD105398"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM133395"],"award-info":[{"award-number":["T32GM133395"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001774","name":"New Jersey Health Foundation","doi-asserted-by":"publisher","award":["PC 44\u201322"],"award-info":[{"award-number":["PC 44\u201322"]}],"id":[{"id":"10.13039\/100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006426","name":"State of New Jersey Department of Health","doi-asserted-by":"publisher","award":["COCR22PRG012"],"award-info":[{"award-number":["COCR22PRG012"]}],"id":[{"id":"10.13039\/100006426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bioactmat.2023.11.014","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T19:15:56Z","timestamp":1703186156000},"page":"125-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-3603","authenticated-orcid":false,"given":"Rachel E.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-1551","authenticated-orcid":false,"given":"Katherine M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel I.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-6510","authenticated-orcid":false,"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-074X","authenticated-orcid":false,"given":"Charalampos","family":"Papachristou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-2966","authenticated-orcid":false,"given":"Jason P.","family":"Gleghorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-5403","authenticated-orcid":false,"given":"Rachel S.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioactmat.2023.11.014_bib1","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA","volume":"2","author":"Islam","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib5","doi-asserted-by":"crossref","first-page":"eaaw1565","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition","volume":"11","author":"Kong","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/gt.2016.46","article-title":"Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system","volume":"23","author":"DeRosa","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib7","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib12","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"First approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib15","article-title":"Lipid nanoparticles for mRNA delivery","volume":"1\u201317","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciadv.aba1028","article-title":"Ionizable lipid nanoparticles for in utero mRNA delivery","volume":"7","author":"Riley","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib17","article-title":"Lipid nanoparticle structure and delivery route during pregnancy dictates mRNA potency, immunogenicity, and health in the mother and offspring","author":"Chaudhary","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jconrel.2019.10.028","article-title":"Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening","volume":"316","author":"Guimaraes","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib20","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114079","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives","volume":"180","author":"Shi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib24","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib25","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1073\/pnas.1620874114","article-title":"Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics","volume":"114","author":"Dahlman","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib28","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201805097","article-title":"Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal pH","volume":"15","author":"Hajj","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.addr.2020.09.006","article-title":"Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy","volume":"160","author":"Figueroa-Espada","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib31","article-title":"Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies","author":"Nelson","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib32","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1021\/jacs.2c12893","article-title":"Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy","volume":"145","author":"Swingle","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib33","doi-asserted-by":"crossref","first-page":"l2381","DOI":"10.1136\/bmj.l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"Burton","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00404-021-06186-5","article-title":"Course of the sFlt-1\/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery","volume":"305","author":"Andrikos","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.clp.2004.06.008","article-title":"Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome","volume":"31","author":"Barton","year":"2004","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11906-014-0473-5","article-title":"Treatment of preeclampsia: current approach and future perspectives","volume":"16","author":"Berzan","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib37","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3389\/fphys.2018.00973","article-title":"Preeclampsia: novel mechanisms and potential therapeutic approaches","volume":"9","author":"Armaly","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajog.2005.12.049","article-title":"Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia","volume":"195","author":"Robinson","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib39","doi-asserted-by":"crossref","first-page":"58 e51","DOI":"10.1016\/j.ajog.2011.07.037","article-title":"The sFlt-1\/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients","volume":"206","author":"Verlohren","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2013.01.004","article-title":"Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia","volume":"3","author":"Saffer","year":"2013","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib42","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt 1 and Flk 1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib43","article-title":"Increased placental sFLT1 (soluble fms-like tyrosine kinase receptor-1) drives the antiangiogenic profile of maternal serum preceding preeclampsia but not fetal growth restriction","author":"Gaccioli","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.119.13360","article-title":"Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis","volume":"74","author":"Agrawal","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.preghy.2011.08.117","article-title":"A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia","volume":"2","author":"Knudsen","year":"2012","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib46","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/jhh.2017.61","article-title":"Placental growth factor and pre-eclampsia","volume":"31","author":"Chau","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228714","article-title":"PlGF immunological impact during pregnancy","volume":"21","author":"Albonici","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/00224065.2013.11917921","article-title":"Definitive screening designs with added two-level factors","volume":"45","author":"Jones","year":"2013","journal-title":"J. Qual. Technol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/00224065.2011.11917841","article-title":"A class of three-level designs for definitive screening in the presence of second-order effects","volume":"43","author":"Jones","year":"2011","journal-title":"J. Qual. Technol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/00401706.2016.1234979","article-title":"Effective design-based model selection for definitive screening designs","volume":"59","author":"Jones","year":"2017","journal-title":"Technometrics"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib51","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib52","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib53","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1038\/ncomms5277","article-title":"Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity","volume":"5","author":"Whitehead","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib55","doi-asserted-by":"crossref","first-page":"8395","DOI":"10.2147\/IJN.S188016","article-title":"Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting","volume":"13","author":"Shobaki","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib56","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib57","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1369\/0022155411410885","article-title":"Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery","volume":"59","author":"Shi","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib59","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib60","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","article-title":"A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation","volume":"18","author":"Paunovska","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib61","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1021\/nn301922x","article-title":"In vitro - in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery","volume":"6","author":"Whitehead","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib62","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcp.2015.04.012","article-title":"Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia","volume":"95","author":"Shah","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib64","doi-asserted-by":"crossref","first-page":"R505","DOI":"10.1152\/ajpregu.00137.2016","article-title":"Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy","volume":"311","author":"Zhu","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","article-title":"Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)","volume":"344","author":"Parhiz","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib66","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.10.015","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib68","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1113\/jphysiol.2008.156133","article-title":"Adaptations in placental nutrient transfer capacity to meet fetal growth demands depend on placental size in mice","volume":"586","author":"Coan","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphys.2016.00028","article-title":"Placental adaptation: what can we learn from birthweight:placental weight ratio?","volume":"7","author":"Hayward","year":"2016","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib70","article-title":"Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age","volume":"36","author":"Irvin-Choy","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib71","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/HYPERTENSIONAHA.109.134668","article-title":"Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice","volume":"54","author":"Suzuki","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib72","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.115.06783","article-title":"Placental growth factor administration abolishes placental ischemia-induced hypertension","volume":"67","author":"Spradley","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib73","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.116.07286","article-title":"Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates","volume":"67","author":"Makris","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib74","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/HYPERTENSIONAHA.121.17047","article-title":"PlGF (placental growth factor) testing in clinical practice: evidence from a Canadian tertiary maternity referral center","volume":"77","author":"McLaughlin","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib75","article-title":"Angiogenic imbalance in pre-eclampsia and fetal growth restriction: enhanced soluble Fms-like tyrosine kinase-1 binding or diminished production of placental growth factor?","author":"Kluivers","year":"2022","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib76","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1242\/jcs.115.12.2559","article-title":"Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability","volume":"115","author":"Odorisio","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib77","first-page":"2749","article-title":"Placental growth factor is a survival factor for tumor endothelial cells and macrophages","volume":"62","author":"Adini","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioactmat.2023.11.014_bib78","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2023.11.014_bib79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0014-4827(90)90310-7","article-title":"Modulators of cyclic AMP metabolism induce syncytiotrophoblast formation in vitro","volume":"186","author":"Wice","year":"1990","journal-title":"Exp. Cell Res."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X23003638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X23003638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:45:27Z","timestamp":1762785927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X23003638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":79,"alternative-id":["S2452199X23003638"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.014","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.22.521490","asserted-by":"object"}]},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}